Edwards Surges on Strong Q1 TMTT Growth, But Valuation Remains Stretched

What happened

Edwards Lifesciences reported strong first-quarter results, with shares surging on growth in its transcatheter mitral and tricuspid therapies (TMTT), which continues to scale rapidly. The DeepValue report had previously highlighted that TMTT is a key growth driver, guiding to $740-780M in 2026, and this quarter's performance validates that trajectory. However, the stock already trades at ~29x 2026 EPS, pricing in sustained double-digit TMTT growth and TAVR expansion. The news does not alter the fundamental risk-reward calculus, as the base case of $90 offers limited upside from current levels around $84. While execution is on track, the market's optimism leaves little room for error, reinforcing our neutral stance.

Implication

The strong Q1 results confirm Edwards' TMTT growth narrative, supporting the stock in the near term. However, with the stock near $84 and 2026 P/E of ~29x, the upside to our base case of $90 is limited. Investors should resist chasing the move and instead wait for a pullback toward the attractive entry zone of $72, where the risk-reward improves. The thesis remains unchanged: high-quality business, but full valuation requires a margin of safety.

Thesis delta

The Q1 beat and TMTT strength reinforce the execution story but do not shift the underlying thesis. The DeepValue report's 'WAIT' rating is maintained, as the stock's premium valuation already embeds this positive momentum. Any sustainable upside requires either a pullback to $72 or evidence of accelerating TAVR growth beyond current guidance.